Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Description of key information

There were two subchronic oral toxicity studies on surrogates available which were conducted according to current guidelines and in compliance with GLP.

Key value for chemical safety assessment

Repeated dose toxicity: via oral route - systemic effects

Endpoint conclusion
Dose descriptor:
300 mg/kg bw/day
Study duration:

Additional information

Two reliable oral subchronic toxicity studies are available for two surrogates that have comparable macro-composition to Saccharomyces cerevisiae, ext.

In the study performed with MDA11 no treatment related effect were found up to the highest dose tested and thus the NOAEL was set at 2000 mg/kg bw/day.

In the study with MBE20 hypertrophy of the urinary bladder epithelium in males and females of the mid- and high-dose groups is considered to be treatment-related. Since the urinary bladder was not affected at the low dose lowel, the NOAEL is placed at 300 mg/kg bw/day.

Repeated dose toxicity: via oral route - systemic effects (target organ) urogenital: urinary bladder

Justification for classification or non-classification

Based on the data available for two surrogates Saccharomyces cerevisiae extract does not need to be classified for repeated dose toxicity according to DSD or CLP.